Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell.

Similar presentations


Presentation on theme: "A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell."— Presentation transcript:

1 A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation  Thomas Fong, Kathryn Trinkaus, Douglas Adkins, Ravi Vij, Steven M. Devine, Michael Tomasson, Lawrence T. Goodnough, Sandra Lopez, Timothy Graubert, Shalini Shenoy, John F. DiPersio, Hanna J. Khoury  Biology of Blood and Marrow Transplantation  Volume 13, Issue 10, Pages (October 2007) DOI: /j.bbmt Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Cumulative incidence of cGVHD for patients enrolled on the HCQ prophylactic trial according to the randomization group and the presence or not of relapse at the time of cGVHD. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Kaplan-Meier overall survival estimate for patients enrolled on the HCQ prophylactic trial according to the randomization group. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Kaplan-Meier relapse-free survival estimate for patients enrolled on the HCQ prophylactic trial according to the randomization group. Median follow-up is 409 days. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions


Download ppt "A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell."

Similar presentations


Ads by Google